PLX.TA - Protalix BioTherapeutics, Inc.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue19,2429,1994,364
Cost of Revenue15,2318,398730
Gross Profit4,0118013,634
Operating Expenses
Research Development28,83424,60820,025
Selling General and Administrative11,5309,3567,279
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-36,353-33,163-23,670
Income from Continuing Operations
Total Other Income/Expenses Net-39,1988,179123
Earnings Before Interest and Taxes-75,551-24,984-23,547
Interest Expense9,7254,1923,735
Income Before Tax-85,276-29,176-27,282
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-85,276-29,176-27,282
Non-recurring Events
Discontinued Operations--18985,319
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-85,276-29,36558,037
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-85,276-29,36558,037